Literature DB >> 16051839

A chimeric respiratory syncytial virus fusion protein functionally replaces the F and HN glycoproteins in recombinant Sendai virus.

Gert Zimmer1, Sascha Bossow, Larissa Kolesnikova, Matthias Hinz, Wolfgang J Neubert, Georg Herrler.   

Abstract

Entry of most paramyxoviruses is accomplished by separate attachment and fusion proteins that function in a cooperative manner. Because of this close interdependence, it was not possible with most paramyxoviruses to replace either of the two protagonists by envelope glycoproteins from related paramyxoviruses. By using reverse genetics of Sendai virus (SeV), we demonstrate that chimeric respiratory syncytial virus (RSV) fusion proteins containing either the cytoplasmic domain of the SeV fusion protein or in addition the transmembrane domain were efficiently incorporated into SeV particles provided the homotypic SeV-F was deleted. In the presence of SeV-F, the chimeric glycoproteins were incorporated with significantly lower efficiency, indicating that determinants in the SeV-F ectodomain exist that contribute to glycoprotein uptake. Recombinant SeV in which the homotypic fusion protein was replaced with chimeric RSV fusion protein replicated in a trypsin-independent manner and was neutralized by antibodies directed to RSV-F. However, replication of this virus also relied on the hemagglutinin-neuraminidase (HN) as pretreatment of cells with neuraminidase significantly reduced the infection rate. Finally, recombinant SeV was generated with chimeric RSV-F as the only envelope glycoprotein. This virus was not neutralized by antibodies to SeV and did not use sialic acids for attachment. It replicated more slowly than hybrid virus containing HN and produced lower virus titers. Thus, on the one hand RSV-F can mediate infection in an autonomous way while on the other hand it accepts support by a heterologous attachment protein.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16051839      PMCID: PMC1182616          DOI: 10.1128/JVI.79.16.10467-10477.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  50 in total

1.  Structure-function analysis of the Sendai virus F and HN cytoplasmic domain: different role for the two proteins in the production of virus particle.

Authors:  N Fouillot-Coriou; L Roux
Journal:  Virology       Date:  2000-05-10       Impact factor: 3.616

2.  The membrane-proximal stem region of vesicular stomatitis virus G protein confers efficient virus assembly.

Authors:  C S Robison; M A Whitt
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

3.  VP40, the matrix protein of Marburg virus, is associated with membranes of the late endosomal compartment.

Authors:  Larissa Kolesnikova; Harald Bugany; Hans-Dieter Klenk; Stephan Becker
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

Review 4.  Molecular mechanism of paramyxovirus budding.

Authors:  Toru Takimoto; Allen Portner
Journal:  Virus Res       Date:  2004-12       Impact factor: 3.303

5.  Functional analysis of recombinant respiratory syncytial virus deletion mutants lacking the small hydrophobic and/or attachment glycoprotein gene.

Authors:  S Techaarpornkul; N Barretto; M E Peeples
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

6.  Proteolytic activation of respiratory syncytial virus fusion protein. Cleavage at two furin consensus sequences.

Authors:  G Zimmer; L Budz; G Herrler
Journal:  J Biol Chem       Date:  2001-06-19       Impact factor: 5.157

7.  Role of matrix and fusion proteins in budding of Sendai virus.

Authors:  T Takimoto; K G Murti; T Bousse; R A Scroggs; A Portner
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

8.  N-glycans of F protein differentially affect fusion activity of human respiratory syncytial virus.

Authors:  G Zimmer; I Trotz; G Herrler
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

9.  The fusion glycoprotein of human respiratory syncytial virus facilitates virus attachment and infectivity via an interaction with cellular heparan sulfate.

Authors:  S A Feldman; S Audet; J A Beeler
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

10.  Recombinant bovine respiratory syncytial virus with deletions of the G or SH genes: G and F proteins bind heparin.

Authors:  Axel Karger; Ulrike Schmidt; Ursula J Buchholz
Journal:  J Gen Virol       Date:  2001-03       Impact factor: 3.891

View more
  10 in total

1.  Recombinant Sendai viruses expressing fusion proteins with two furin cleavage sites mimic the syncytial and receptor-independent infection properties of respiratory syncytial virus.

Authors:  Joanna Rawling; Olga Cano; Dominique Garcin; Daniel Kolakofsky; José A Melero
Journal:  J Virol       Date:  2011-01-12       Impact factor: 5.103

2.  Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed by a Parainfluenza Virus Vector.

Authors:  Bo Liang; Joan O Ngwuta; Richard Herbert; Joanna Swerczek; David W Dorward; Emerito Amaro-Carambot; Natalie Mackow; Barbora Kabatova; Matthias Lingemann; Sonja Surman; Lijuan Yang; Man Chen; Syed M Moin; Azad Kumar; Jason S McLellan; Peter D Kwong; Barney S Graham; Anne Schaap-Nutt; Peter L Collins; Shirin Munir
Journal:  J Virol       Date:  2016-10-14       Impact factor: 5.103

3.  Unraveling the entry mechanism of baculoviruses and its evolutionary implications.

Authors:  Manli Wang; Jue Wang; Feifei Yin; Ying Tan; Fei Deng; Xinwen Chen; Johannes A Jehle; Just M Vlak; Zhihong Hu; Hualin Wang
Journal:  J Virol       Date:  2013-12-11       Impact factor: 5.103

4.  Improved Prefusion Stability, Optimized Codon Usage, and Augmented Virion Packaging Enhance the Immunogenicity of Respiratory Syncytial Virus Fusion Protein in a Vectored-Vaccine Candidate.

Authors:  Bo Liang; Joan O Ngwuta; Sonja Surman; Barbora Kabatova; Xiang Liu; Matthias Lingemann; Xueqiao Liu; Lijuan Yang; Richard Herbert; Joanna Swerczek; Man Chen; Syed M Moin; Azad Kumar; Jason S McLellan; Peter D Kwong; Barney S Graham; Peter L Collins; Shirin Munir
Journal:  J Virol       Date:  2017-07-12       Impact factor: 5.103

Review 5.  Targeting RSV with vaccines and small molecule drugs.

Authors:  Heather M Costello; William C Ray; Supranee Chaiwatpongsakorn; Mark E Peeples
Journal:  Infect Disord Drug Targets       Date:  2012-04

6.  A Respiratory Syncytial Virus Vaccine Vectored by a Stable Chimeric and Replication-Deficient Sendai Virus Protects Mice without Inducing Enhanced Disease.

Authors:  Marian Alexander Wiegand; Gianni Gori-Savellini; Claudia Gandolfo; Guido Papa; Christine Kaufmann; Eva Felder; Alessandro Ginori; Maria Giulia Disanto; Donatella Spina; Maria Grazia Cusi
Journal:  J Virol       Date:  2017-04-28       Impact factor: 5.103

Review 7.  Analysis of Human RSV Immunity at the Molecular Level: Learning from the Past and Present.

Authors:  Kerrie Vaughan; Julia Ponomarenko; Bjoern Peters; Alessandro Sette
Journal:  PLoS One       Date:  2015-05-22       Impact factor: 3.240

8.  Differential sensitivity of bat cells to infection by enveloped RNA viruses: coronaviruses, paramyxoviruses, filoviruses, and influenza viruses.

Authors:  Markus Hoffmann; Marcel Alexander Müller; Jan Felix Drexler; Jörg Glende; Meike Erdt; Tim Gützkow; Christoph Losemann; Tabea Binger; Hongkui Deng; Christel Schwegmann-Weßels; Karl-Heinz Esser; Christian Drosten; Georg Herrler
Journal:  PLoS One       Date:  2013-08-30       Impact factor: 3.240

9.  1-Benzyl-3-cetyl-2-methylimidazolium Iodide (NH125) Is a Broad-Spectrum Inhibitor of Virus Entry with Lysosomotropic Features.

Authors:  Sarah Moeschler; Samira Locher; Gert Zimmer
Journal:  Viruses       Date:  2018-06-05       Impact factor: 5.048

10.  Sendai virus-based immunoadjuvant in hydrogel vaccine intensity-modulated dendritic cells activation for suppressing tumorigenesis.

Authors:  Bin Zheng; Wenchang Peng; Lin Gan; Mingming Guo; Shuchao Wang; Xiao-Dong Zhang; Dong Ming
Journal:  Bioact Mater       Date:  2021-04-13
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.